Laurus Labs posted consolidated net profit for quarter ended March 31, 2025 at Rs. 233.87 crore from Rs. 75.32 crore a year earlier on a 19% increase in the revenue.

Revenue from operations for the fourth quarter rose to Rs. 1,720.30 crore (Rs. 1,439.67 crore) boosted by 85% increase in CDMO business revenue to Rs. 490 crore (Rs. 265 crore). Revenue from the mainstay generics business increased 5% to Rs. 1,230 crore (Rs. 1,175 crore).

For 2024-25, net profit increased to Rs. 354.41 crore (Rs. 168.21 crore) and revenue from operations rose to Rs. 5,553.96 crore (Rs. 5,040.83 crore). The company attributed the higher revenues to robust demand environment for CDMO offering and higher FDF sales.

Dr. Satyanarayana Chava, Founder & Chief Executive Officer commented: “We delivered a very good Q4 results and continued our transformative progress, reflecting robust demand for our CDMO offerings and meeting complex customer needs, supported by growth in FDF division. These results demonstrate the strength of our business model and give us confidence in our outlook. We are deepening our cooperation with major clients, and augmenting it with promising BD and capacity creation.

“Our business remains well positioned to evolve into a well-diversified CMO/CDMO company with promising pipeline, enabling several technology platforms and commercial excellence, thanks to team commitment to the unified vision of delivering high quality integrated solution and securing our long-term growth potential.”

V V Ravi Kumar, Executive Director & Chief Financial Officer commented: “Despite the ongoing macroeconomic challenges, we have witnessed high level of demand for our offerings. For Q4, we delivered Rs. 1,720 Cr in revenues, growth of 19% and Rs. 477 Cr EBITDA grew by 84%, resulting in 27.7% margin. Gross margins remained healthy at 55% due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy.

“Overall FY25 results, we have delivered revenues of Rs. 5,554 Cr, representing 10% growth and EBITDA stood at Rs. 1,115 Cr, growth of 40%. The EBITDA margin of 20.1% has substantially improved, supported by continuing operating leverage within CDMO business.

“Going ahead, we remain confident in our growth expectations as we look forward to execute on long lead programs, new assets ramp up with revenue increasing over FY25 with continued focus on operational excellence. Our capital allocation strategy remain unchanged, prioritizing investments into high value business opportunities.”